You are viewing: US Hemostats Market analysis
Part of: Hemostats Market (Global)

The US Hemostats Market was valued at $345.3 Million in 2025 and projected to reach to $468.5 Million by 2030, representing a compound annual growth rate of 6.3%. The US hemostats market is poised for sustained growth driven by increasing surgical volumes, aging population demographics, and rising prevalence of chronic conditions requiring surgical intervention.

US Hemostats Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Hemostats Market Trends and Insights

  • The US market benefits from advanced surgical infrastructure, high healthcare spending, and increasing adoption of minimally invasive procedures that drive demand for effective hemostatic agents.
  • In the US, the market is supported by strong regulatory frameworks, robust reimbursement policies, and a well-established distribution network for surgical products. Growth in the US hemostats market is fueled by rising surgical volumes, an aging population requiring more surgical interventions, and technological innovations in hemostatic formulations.
  • The US healthcare system's emphasis on reducing blood loss complications and improving patient outcomes accelerates adoption of advanced hemostats.
  • Between 2025 and 2030, the US market will continue to benefit from increased hospital investments in surgical capabilities and growing awareness among healthcare providers of hemostatic solutions..

Key Market Statistics

  • CAGR (2025-2030) 6.3% CAGR
  • Market Size, 2025 ~USD 345.3 Million
  • Forecast, 2030 ~USD 468.5 Million
  • Country US

US Hemostats Market Overview

Market Size & Growth :

The US hemostats market is valued at $345.3 million in 2025 and is projected to reach $468.5 million by 2030, representing a steady CAGR of 6.3% over the forecast period.

Advanced Surgical Infrastructure :

The US benefits from world-class surgical facilities and high healthcare spending, creating strong demand for premium hemostatic solutions across hospitals and surgical centers nationwide.

Minimally Invasive Procedure Adoption :

Increasing adoption of minimally invasive surgical techniques in the US drives demand for effective hemostatic agents that can be deployed through smaller incisions with precision.

Regulatory & Innovation Environment :

The US market is characterized by robust FDA approval pathways and continuous innovation in hemostatic technologies, supporting new product launches and market expansion.

US Hemostats Market Dynamics

  • Healthcare providers are increasingly investing in advanced hemostatic solutions to improve patient outcomes and reduce operative complications.
  • The shift toward value-based care and cost-effective surgical practices further supports market expansion.
  • Additionally, technological advancements in hemostatic agents and growing adoption across outpatient surgical centers present significant growth opportunities.
  • Market consolidation and strategic partnerships among key players are expected to shape competitive dynamics through 2030..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • JOHNSON & JOHNSON

    Key Takeaways

    • The US hemostats market is valued at $345.3 million in 2025 and will reach $468.5 million by 2030, growing at 6.3% CAGR.
    • The US market is driven by advanced surgical infrastructure, high healthcare spending, and adoption of minimally invasive procedures.
    • Strong regulatory frameworks and robust reimbursement policies in the US support market expansion and product adoption.
    • Rising surgical volumes and an aging US population are key growth drivers for hemostatic product demand through 2030.

    Hemostats Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment RECONSTRUCTIVE SURGERY (Application)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.4% from 2025 to 2030
    Largest Segment HOSPITALS (End User)
    Market Size Base Year (Billions) ~USD 2.93 (2025)
    Revenue Forecast (Billions) ~USD 4 (2030)
    Segments Covered Type, Formulation, Application, End User

    US Hemostats Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Collagen-Based Hemostats
    • Combination Hemostats
    • Gelatin-Based Hemostats
    • Other Types
    • Oxidized Regenerated Cellulose-Based Hemostats
    • Thrombin-Based Hemostats

    By Formulation

    • Matrix & Gel Hemostats
    • Powder Hemostats
    • Sheet & Pad Hemostats
    • Sponge Hemostats

    By Application

    • Cardiovascular Surgery
    • General Surgery
    • Gynecological Surgery
    • Neurological Surgery
    • Orthopedic Surgery
    • Other Surgeries
    • Reconstructive Surgery

    By End User

    • Hospitals
    • Specialty Clinics

    US: HEMOSTATS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOSPITALS750.4795843.3895.7952.71014.71082.311566.5
    OTHERS125128.9133.1137.6142.4147.6153.2159.33.7
    SPECIALTY CLINICS251.3263275.7289.4304.1320337.33565.2
    TOTAL1126.71186.91252.11322.71399.21482.31572.81671.35.9

    Target Audience

    • Medical Device Manufacturers : Manufacturers need US-specific market data to develop product portfolios, identify market gaps, and plan commercial launches aligned with American surgical practice patterns and regulatory requirements.
    • Healthcare Investors & PE Firms : Investors require detailed US market analysis to evaluate investment opportunities, assess portfolio company growth potential, and make informed decisions on healthcare sector allocations.
    • Hospital & Surgical Center Administrators : Healthcare facility leaders need market insights to optimize procurement strategies, evaluate supplier partnerships, and ensure access to cost-effective hemostatic solutions for their surgical programs.
    • Pharmaceutical & Biotech Companies : Companies developing hemostatic products need US market intelligence to guide R&D investments, clinical trial planning, and commercialization strategies for the American market.
    • Healthcare Consultants & Analysts : Consultants require comprehensive US market data to support client advisory work, competitive benchmarking, and strategic recommendations across the hemostats industry.

    Key Companies in the US Hemostats Market

    CompanyHQOwnershipStrongest segments
    CSL LIMITEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BAXTERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    PFIZER INC.United StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BECTON, DICKINSON AND COMPANY (BD)United States
    TELEFLEX INCORPORATEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    MEDTRONIC PLCIrelandPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    STRYKERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    INTEGRA LIFESCIENCESUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    ADVANCED MEDICAL SOLUTIONS GROUP PLCUnited KingdomPublic CompanyGelatin-based hemostats,Collagen-based hemostats,Combination hemostats and biosurgical adjuncts,
    SAMYANG CORPORATIONKorea, Republic ofPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,

    CSL LIMITED

    CSL LIMITED is a public company founded in 1916 and headquartered in the United States, employing 29,904 people. The company operates in the biotechnology and pharmaceutical sectors.

    BAXTER

    BAXTER is a public company founded in 1931 in the United States, employing 37,500 people. The company operates in the medical devices and pharmaceutical sectors.

    PFIZER INC.

    PFIZER INC. is a public company founded in 1950 in the United States with 1,244 employees. The company operates in the pharmaceutical and healthcare industry.

    BECTON, DICKINSON AND COMPANY (BD)

    BECTON, DICKINSON AND COMPANY (BD) is a company headquartered in the United States. The company operates in the medical devices and healthcare sectors.

    TELEFLEX INCORPORATED

    TELEFLEX INCORPORATED is a public company founded in 1943 in the United States, employing 15,500 people. The company manufactures medical devices and specialty healthcare products.

    MEDTRONIC PLC

    MEDTRONIC PLC is a public company founded in 1949 and headquartered in Ireland, employing 95,000 people. The company is a global leader in medical technology and healthcare solutions.

    STRYKER

    STRYKER is a public company founded in 1941 in the United States, employing 56,000 people. The company is a leading manufacturer of medical devices and surgical equipment.

    INTEGRA LIFESCIENCES

    INTEGRA LIFESCIENCES is a public company founded in 1989 in the United States, employing 4,427 people. The company develops and manufactures medical devices and regenerative medicine products.

    ADVANCED MEDICAL SOLUTIONS GROUP PLC

    ADVANCED MEDICAL SOLUTIONS GROUP PLC is a public company founded in 1991 in the United Kingdom, employing 1,800 people. The company specializes in advanced wound care and medical device solutions.

    SAMYANG CORPORATION

    SAMYANG CORPORATION is a public company founded in 1961 in the Republic of Korea, employing 1,994 people. The company operates in the chemical and pharmaceutical manufacturing sectors.

    Reasons to Buy this Report

    • Precise US Market Sizing : Access validated market size data specific to the United States ($345.3M in 2025), enabling accurate budgeting and resource allocation for US-focused business strategies.
    • Competitive Intelligence : Understand the competitive landscape within the US market, including key players, market share dynamics, and strategic positioning to inform competitive strategy and market entry decisions.
    • Growth Opportunity Identification : Identify high-growth segments and emerging opportunities within the US hemostats market driven by minimally invasive procedures and advanced surgical infrastructure adoption.
    • Regulatory & Reimbursement Insights : Gain clarity on US-specific regulatory requirements, FDA approval pathways, and reimbursement landscape critical for product development and commercialization planning.
    • Strategic Planning & Forecasting : Leverage 5-year forecast data (2025-2030) to develop long-term strategic plans, investment decisions, and market expansion initiatives tailored to US market dynamics.

    Frequently asked questions

    What is the current size of the US hemostats market?

    The US hemostats market is valued at $345.3 million in 2025 and is expected to grow to $468.5 million by 2030.

    What is the growth rate of the US hemostats market?

    The US hemostats market is projected to grow at a compound annual growth rate of 6.3% from 2025 to 2030.

    What factors are driving growth in the US hemostats market?

    Key drivers include rising surgical volumes, an aging population, technological innovations in hemostatic formulations, and increased hospital investments in surgical capabilities.

    How does the US hemostats market compare to other regions?

    The US market benefits from advanced surgical infrastructure, strong regulatory frameworks, robust reimbursement policies, and a well-established distribution network that support faster adoption compared to many other regions.

    What role does reimbursement play in the US hemostats market?

    Robust reimbursement policies in the US healthcare system encourage hospitals and surgical centers to adopt advanced hemostatic solutions, directly supporting market growth and product innovation.

    RESEARCH METHODOLOGY

    The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, as well as the competitive landscape of the hemostats market, to analyze market players on various parameters within the broad categories of business and product strategy. Top-down approach was used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involved extensive use of various secondary sources, including directory databases like Bloomberg Business, Factiva, and D&B Hoovers, white papers, annual reports, company house documents, investor presentations, and SEC filings. This research was conducted to gather information valuable for a comprehensive, technical, market-oriented, and commercial study of the hemostats market. It also helped obtain critical insights about key players in the industry, market classification, and segmentation based on current industry trends down to the finest details. Additionally, a database of leading industry players was created through this secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

    A breakdown of the primary respondents for the hemostats market is provided below:

    Hemostats Market

    Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

    Note 2: Others include sales, marketing, and product managers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The research methodology used to estimate the size of the hemostats market includes the following details.

    The market sizing was undertaken from the global side.

    Top-down was used to estimate and validate the hemostats market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • Primary and secondary research has determined the revenues generated by leading players operating in the hemostats market.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Hemostats Market Size: Top-down Approach

    Hemostats Market

    Data Triangulation

    After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    During surgical procedures, damage to blood vessels necessitates immediate intervention to mitigate hemorrhage—this process is referred to as hemostasis. Hemostatic agents work by facilitating the formation of fibrin clots, providing an interim solution to manage bleeding at the site. The application of hemostatic measures must be executed rapidly, precisely localized, and meticulously regulated, particularly in scenarios involving significant blood loss or in patients with congenital coagulopathies or trauma-induced vascular compromise.

    Stakeholders

    • Senior Management
    • Finance Department
    • Procurement Department
    • Hospitals
    • Specialty Clinics
    • Trade Associations and Industry Bodies
    • Regulatory Bodies and Government Agencies
    • Business Research & Consulting Service Providers
    • Market Research & Consulting Firms
    • Venture Capitalists and Investors

    Report Objectives

    • To define, describe, segment, analyze, and forecast the hemostats market by type, formulation, application, end user, and region
    • To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the hemostats market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile the key players in the hemostats market and comprehensively analyze their core competencies
    • To track and analyze competitive developments such as agreements, collaborations, and partnerships; expansions; acquisitions; and product launches & approvals in the hemostats market

     

    Get the Full Hemostats Market Report

    Full forecast, segment splits, and company analysis for all Hemostats Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status